TY - JOUR
T1 - Genetic diversity of integrase (IN) sequences in antiretroviral treatment-naive and treatment-experienced HIV type 2 patients
AU - Xu, L.
AU - Anderson, J.
AU - Ferns, B.
AU - Cook, P.
AU - Wildfire, A.
AU - Workman, J.
AU - Graham, S.
AU - Smit, E.
PY - 2008/7/1
Y1 - 2008/7/1
N2 - Two potent integrase inhibitors (IN-Is), raltegravir (RAL, MK-0518) and elvitegravir (EGV, GS-9137), have been shown to be potent inhibitors for HIV-1 and resistance mutations have been identified in HIV-1 clinical trials. In this study, sequences from 11 HIV-2 patients were examined for IN polymorphisms. The primary mutations associated with RAL and EGV resistance were not detected despite the genetic variability among clinical isolates. Our study provides basic information on genotypic susceptibility of HIV-2 to RAL and EGV and supports the suggestion that RAL and EGV could be considered as a new therapeutic option for treating HIV-2-infected patients.
AB - Two potent integrase inhibitors (IN-Is), raltegravir (RAL, MK-0518) and elvitegravir (EGV, GS-9137), have been shown to be potent inhibitors for HIV-1 and resistance mutations have been identified in HIV-1 clinical trials. In this study, sequences from 11 HIV-2 patients were examined for IN polymorphisms. The primary mutations associated with RAL and EGV resistance were not detected despite the genetic variability among clinical isolates. Our study provides basic information on genotypic susceptibility of HIV-2 to RAL and EGV and supports the suggestion that RAL and EGV could be considered as a new therapeutic option for treating HIV-2-infected patients.
UR - http://www.scopus.com/inward/record.url?scp=48749125376&partnerID=8YFLogxK
U2 - 10.1089/aid.2007.0303
DO - 10.1089/aid.2007.0303
M3 - Article
C2 - 18593344
AN - SCOPUS:48749125376
SN - 0889-2229
VL - 24
SP - 1003
EP - 1007
JO - AIDS Research and Human Retroviruses
JF - AIDS Research and Human Retroviruses
IS - 7
ER -
